搜尋結果
1538P - A phase II study to evaluate the efficacy and safety of tislelizumab combined with chemotherapy (cis-platinum plus albumin-paclitaxel/paclitaxel) in neoadjuvant treatment of locally advanced oesophageal squamous cell carcinoma
A prospective, open, single-arm, two-cohort phase II trial was conducted. ESCC Pts with resectable locally advanced disease were enrolled and randomly allocated into group nab-PTX (group A) or group PTX (group B).
1538P A phase II study to evaluate the efficacy and safety of tislelizumab combined with chemotherapy (cis-platinum plus albumin-paclitaxel/paclitaxel) in neoadjuvant treatment of locally advanced oesophageal squamous cell carcinoma
TOW-1538P-C3310-R PUI Audio 擴音器 MICROPHONE -38DB 2VDC 資料表、庫存和定價。
- PUI Audio
This study is a multicentre, single-arm, open-label phase II study. Patients with histologically confirmed cT2-4NxM0 or cTxN+M0, (TNM 8th edition), resectable GC/GEJC are eligible for this study. Neoadjuvant therapy will be administered for four cycles.
2019年10月1日 · Results. A total of n = 283 EGFR + NSCLC patients received erlotinib (45%), gefitinib (19%) and/or afatinib (36%) in the 1 st -4 th treatment lines with a median age of 66 years, a median ECOG performance status of 0 (137/266 patients with available data) and a predominance of female (183/283=65%) never-/light-smokers (177/283=63%).
Micard Plus (Card reader for identification with RFID or magnetic cards with uniFLOW) Streamline your print processes with rapid print, dual network support and an expandable paper capacity of up to 2,300 sheets. uniFLOW Online Express as standard.
